Glycogen phosphorylase BB levels are associated with haemodynamic parameters in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt insertion

Martina Vasatová, Radek Pudil, Tomas Buchler, Iva Karasová, Vaclav Safka, Tomas Fejfar, Petr Hulek

Background. Transjugular intrahepatic portosystemic shunts (TIPS) have become a widely accepted tool in the treatment of patients with symptomatic portal hypertension. The aim of our study was to assess glycogen phosphorylase BB (GPBB) concentration in relation to echocardiographic and haemodynamic parameters in patients before and after TIPS insertion.

Methods. The study population consisted of 55 patients (38 men and 17 women, age 55.6±8.9 years, range 37-74 years) with liver cirrhosis treated with transjugular portosystemic shunting. GPBB, echocardiographic, and haemodynamic parameters were measured before TIPS insertion and 24 h after the procedure. GPBB concentrations were assessed using the Cardiac Array for Evidence Investigator protein biochip. Correlation between parameters was assessed using the Spearman’s coefficient.

Results. Serum post-procedural GPBB concentrations were increased in comparison with baseline (5.58 vs. 2.67 μg/L, \(P<0.001\)). GPBB concentration after TIPS significantly correlated with baseline systemic vascular resistance (\(r=0.330\); \(P=0.017\)) and cardiac index (\(r=0.313\); \(P=0.025\)).

Conclusion. GPBB concentration measurement may be a useful tool for monitoring myocardial ischemia during a TIPS procedure.

Key words: glycogen phosphorylase BB, cardiac marker, cirrhosis, biochip, portal hypertension, TIPS

INTRODUCTION

Portal hypertension is the main cause for the development of esophago-gastric varices, ascites and hepatic nephropathy in liver cirrhosis. Transjugular intrahepatic portosystemic shunts (TIPS) have become widely accepted for the treatment of patients with symptomatic portal hypertension. TIPS decreases the portal pressure by redirecting portal blood volume into the systemic venous circulation. However, subsequent marked increase in ventricular preload can precipitate cardiac dysfunction¹. Several studies have reported changes in echocardiography and invasive haemodynamic monitoring parameters after TIPS insertion. Huonker et al. observed an increase in the left atrial diameter, left ventricular end diastolic volume, pulmonary capillary wedge pressure, right atrial pressure, cardiac output, and total pulmonary resistance after TIPS procedure². These changes reflect diastolic dysfunction occurring after TIPS. Schwartz et al. reported that congestive heart failure developed in 13% patients after TIPS insertion³. Bernal et al. and Henriksen et al. found high level of NT-proBNP levels in cirrhotic patients possibly due to diastolic dysfunction and central volume expansion⁴,⁵. On the other hand, there are only several studies measuring cardiac necrosis markers in relation to TIPS procedure⁶,⁷. In the last decade, the armamentarium of cardiac markers has expanded to include several molecules that are potentially useful for the diagnosis of cardiac injury and are awaiting validation for routine clinical applications. These novel analytes include glycogen phosphorylase BB isoenzyme (GPBB) as marker of myocardial ischemia and necrosis⁸.

The aim of our study was to measure GPBB concentrations to assess their relationship to echocardiographic and haemodynamic parameters in patients before TIPS insertion - mainly increased heart rate, cardiac output (cardiac index), and reduced systemic vascular resistance.

MATERIALS AND METHODS

Study population

Patients with liver cirrhosis regardless of aetiology requiring the insertion of TIPS were enrolled in the study.
Table 1. Shows patient demographic characteristics.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Men n (%)</th>
<th>Women n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>38 (69)</td>
<td>17 (31)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>55.6 ± 8.9</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>55.1 ± 9.4</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>55.8 ± 8.7</td>
<td></td>
</tr>
<tr>
<td>Aetiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>36 (65)</td>
<td></td>
</tr>
<tr>
<td>Viral</td>
<td>7 (13)</td>
<td></td>
</tr>
<tr>
<td>NASH</td>
<td>6 (11)</td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>2 (4)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>4 (7)</td>
<td></td>
</tr>
<tr>
<td>Child-Pugh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>score points</td>
<td>8.7 ± 1.5</td>
<td></td>
</tr>
<tr>
<td>Child</td>
<td></td>
<td></td>
</tr>
<tr>
<td>classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A n (%)</td>
<td>7 (13)</td>
<td></td>
</tr>
<tr>
<td>B n (%)</td>
<td>32 (58)</td>
<td></td>
</tr>
<tr>
<td>C n (%)</td>
<td>16 (29)</td>
<td></td>
</tr>
</tbody>
</table>

SD - standard deviation, NASH - non-alcoholic steatohepatitis.

Table 2. Shows haemodynamic and echocardiographic parameters.

<table>
<thead>
<tr>
<th></th>
<th>Before TIPS</th>
<th>24 h after TIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echocardiographic parameters:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA (mm)</td>
<td>39.5 (36.2-43.4)</td>
<td>38.5 (34.42.2)</td>
</tr>
<tr>
<td>RV (mm)</td>
<td>27 (25-29)</td>
<td>28 (26-30)</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>31.5 (30.1-33.4)</td>
<td>30 (27.2-34.8)</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>47.0 (44.7-51.2)</td>
<td>46.0 (44.6-48.7)</td>
</tr>
<tr>
<td>IVC (mm)</td>
<td>17.0 (15.5-19.0)</td>
<td>17.0 (15.1-19.4)</td>
</tr>
<tr>
<td>PCWP (mmHg)</td>
<td>9.5±1.9</td>
<td>10.7±3.6 *</td>
</tr>
<tr>
<td>CO (L/min)</td>
<td>7.2±1.7</td>
<td>9.5±1.9 ***</td>
</tr>
<tr>
<td>CI (L/min/m²)</td>
<td>4.3 ± 2.3</td>
<td>5.2± 1.1 *</td>
</tr>
<tr>
<td>SVR (dyn.sec/cm²)</td>
<td>908±277</td>
<td>631±133 ***</td>
</tr>
<tr>
<td>PVR (dyn.sec/cm²)</td>
<td>89.3±51.6</td>
<td>82.3±43.3</td>
</tr>
</tbody>
</table>

| Hemodynamic parameters: |             |                 |
| E (cm/s)               | 75.5 (60.5-87.3) | 88.0 (74.3-109.7) ** |
| A (cm/s)               | 85.1(76.2-99.5)  | 91.2 (81.5-104.5) * |
| E/A                    | 0.887192       | 0.964912 *       |
| DT-E (ms)              | 210 (165-265)  | 175 (134-230) * |
| IVRT (ms)              | 70.2 (63.0-80.4) | 75.0 (62.5-89.5) * |

median (interquartile range) or average ± SD, * P<0.05, ** P<0.01, ***P<0.001, CO - cardiac output, CI - cardiac index, SVR - systemic vascular resistance, PVR-pulmonary vascular resistance, PCWP - pulmonary capillary wedge pressure, LVEDD - left ventricular end-diastolic diameter, LVESD - left ventricular end-systolic diameter, LA- left atrium diameter, RV - right ventricle diameter, EF- left ventricular ejection fraction, E - peak early filling velocity, A - peak late atrial filling velocity, DT-E deceleration time of E velocity, IVRT- isovolumic relaxation time, IVC - inferior vena cava diameter.

Patients were required to be in a stable condition with no gastrointestinal bleeding during the 15 days preceding the TIPS insertion. Medication affecting haemodynamics, such as β-blockers and vasodilators, was stopped at least 10 days before TIPS. Diuretics were kept constant during the week before the TIPS insertion. Patency of the shunt was evaluated using the Doppler ultrasound during regular follow-up. The study protocol was approved by the local Ethics Committee. Informed consent was obtained from each patient.

Haemodynamic monitoring

All patients were monitored using Swan-Ganz pulmonary catheter inserted in the pulmonary circulation before the TIPS procedure. The haemodynamic parameters including heart rate, blood pressure, cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR), and pulmonary capillary wedge pressure (PCWP) were measured before the procedure and 24 h after the TIPS insertion.

Echocardiography was performed in agreement with the American Society of Echocardiography standards evaluating the following parameters: left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameters, left atrium diameter (LA), right ventricle diameter (RV), end-diastolic septal and posterior wall thickness, inferior vena cava diameter (IVC), LV ejection fraction, peak early filling velocity (E), peak late atrial filling velocity (A), E/A ratio, deceleration time of E velocity (DT-E) and isovolumic relaxation time (IVRT).

Measurement of GPBB

GPBB concentrations were measured in peripheral venous sample before the procedure and 24 h after the procedure. Blood samples were obtained by venepuncture, immediately shipped to the laboratory and centrifuged (2500 g, 10 min) within one hour of collection. Serum samples were stored at -70 °C until analysis (within nine months).

GPBB concentrations were measured using the Evidence Investigator protein biochip system (Randox Laboratories, UK). Simultaneous quantitative detection of multiple analytes based on sandwich chemiluminescent immunoassay was carried out from a single patient sample. The core technology consists of a solid plate containing discrete test regions with immobilised antibodies specific to different cardiac markers. Increased levels of cardiac markers in a specimen lead to increased binding of antibody labelled with horseradish peroxidase and thus to an increase in the luminescent signal emitted. The light signals generated from each of the test regions on the bio-
chip are simultaneously detected using a charge coupled
device (CCD) camera.

The analytical sensitivity of the GPBB assay was
0.65 μg/L. We have used the cut-off value 7.3 μg/L as
recommended by the manufacturer. The interassay coef-
ficient of variability (n=10) was in accordance with data
provided by the manufacturer in the range of CV=2.0-
9.8% (8.4 μg/L - 6.6%, 68.1 μg/L - 7.9%). Internal quality
control measurements were carried out using samples
provided by the kit manufacturer.

Statistical analysis

Normality was tested using the Kolmogorov-Smirnov
test. Normally distributed data are reported as means ±
standard deviation, while non-normal data as median
and interquartile range. Statistical comparisons carried
out using paired Wilcoxon test for data with non-normal
distribution and using paired t-tests for data with normal
distribution. Differences with \( P < 0.05 \) were considered
statistically significant. Degree of association between
continuous data was calculated using the Spearman’s
correlation coefficient.

RESULTS

The study population consisted of 55 consecutive pa-
tients (38 men and 17 women, age 55.6± 8.9 years) with
liver cirrhosis treated with elective transjugular portosys-
temic shunting. The cause of liver disease were alcohol
consumption in 36 (65%) patients, viral hepatitis 7 (13%)
patients, non-alcoholic steatohepatitis in 6 (11%) patients,
autoimmune hepatitis in 2 (4%) patients, and cryptogenic
in 4 (7%) patients. The demographic characteristics are
shown in Table 1.

Haemodynamic and echocardiographic parameters in
patients before and 24 h after TIPS are shown in Table 2.
Before the procedure, serum GPBB concentrations were
increased over the cut-off value 7.3 μg/L in 12.0 % of pa-
tients. Statistically significant increases in serum levels
of GPBB in comparison with pre-procedural levels was
detected in samples obtained 24 h after TIPS (2.67 (2.00-
5.33) μg/L vs. 5.58 (2.41-14.18) μg/L, \( P < 0.001 \)). In 40%
of patients, the level was above the cut-off value.

GPBB is a sensitive marker of saccharide metabolism
in cardiomyocytes and this alteration was probably linked
to changes in myocardial metabolism without myocar-
dial necrosis during the procedure. We have found an
association between GPBB measured 24 h after TIPS
insertion with systemic vascular resistance (SVR) (Fig.
1) and cardiac index (CI) (Fig. 2) assessed before the
procedure. The Spearman’s coefficient values were as fol-
lows: GPBB vs. SVR: \( r=0.330 (P=0.017) \); GPBB vs. CI:
\( r=0.313 (P=0.025) \).

DISCUSSION

The transjugular intrahepatic portosystemic shunt is
widely used to treat portal hypertension-related compli-
cations. TIPS may impair cardiac function and haemo-
dynamics. In particular, it rapidly shifts a large volume
of blood from the splanchnic area to the heart, thus in-
creasing the cardiac preload. Liver cirrhosis is frequently
associated with cardiac dysfunction (cirrhotic cardiomy-
opathy) and circulation abnormalities.

To our knowledge, this is the first report on GPBB
association with haemodynamic parameters in patients
undergoing TIPS insertion. According to a recent defini-
tion of myocardial infarction, cardiopause troponins
are recommended for the detection of myocardial injury
as cardiac markers of the first choice\(^8,10\). However, we
found no differences in concentrations of common car-
diac markers\(^7\). In contrast, a significant increase in the
serum GPBB concentration occurred during TIPS inser-
tion. GPBB is a glycolytic enzyme that plays an essen-
tial role in the regulation of carbohydrate metabolism. It
catalyzes the first step of glycogenolysis, where glycogen
is converted to glucose 1-phosphate by phosphorylation
in the presence of inorganic phosphate, and through

Fig. 1. Association of serum GPBB measured 24 h after TIPS
with systemic vascular resistance (SVR) before TIPS.

Fig. 2. Association of serum GPBB measured 24 h after TIPS
with cardiac index (CI) before TIPS.
mobilization of glycogen, it is primarily associated with provision of an emergency glucose supply during periods of hypoxia and hypoglycemia. Under normal conditions, GPBB is structurally bound to macromolecular complex in the sarcoplasmatic reticulum. With the onset of tissue ischemia, GPBB is converted to a free soluble form and diffuses out of the cell if the membrane permeability is simultaneously increased. GPBB usually peaks 6-20 h after myocardial infarction onset and returned within the reference interval within 1–2 days\textsuperscript{11}. Diagnostic sensitivity and specificity GPBB for myocardial infarction diagnosis are 0.81 and 0.93, respectively. The area under ROC curve is 0.85-0.87 (ref.\textsuperscript{12}).

GPBB is a promising enzyme for the laboratory detection of early ischemic myocardial damage\textsuperscript{8}. The GPBB concentration increase during TIPS may be linked to changes in myocardial metabolism without myocardial necrosis during the procedure.

We found an association between the serum GPBB levels measured 24 h after the TIPS insertion and hemodynamic parameters including systemic vascular resistance and cardiac index assessed before the procedure. Cardiac output and cardiac index are dependent on the left ventricle function. After the TIPS procedure, both cardiac output and cardiac index increase because of the decrease in systemic vascular resistance. Therefore, the positive association of GPBB with systemic vascular resistance and negative association with cardiac index probably indicates decreased cardiac contractile reserve. This observation can be helpful for identifying patients with increased cardiovascular risk. Positivity of GPBB in patients with negativity of other cardiomarkers suggests that GPBB could be a more sensitive marker for detection of acute cardiac injury. Horacek et al. reported increased GPBB associated with cardiotoxicity caused by anticancer therapy\textsuperscript{11}.

However, hepatic encephalopathy is also a common complication following the insertion of TIPS and GPBB is also the predominant isoenzyme in the human brain. Much lower GPBB concentrations have been reported in leukocytes, platelets, spleen, kidney, bladder, testis, digestive tract and aorta. On the other hand, the liver contains predominantly the GPLL isoenzyme GPLL.

CONCLUSIONS

Our study was a pilot non-randomized study with a relatively small number of cirrhotic patients undergoing a TIPS procedure. Our results show that 1) serum post-procedural GPBB concentrations are increased in comparison with baseline; 2) serum post-procedural GPBB concentrations are associated with hemodynamic parameters including systemic vascular resistance and cardiac index. The GPBB may be a useful tool for monitoring myocardial ischemia occurring during the TIPS procedure.

ABBREVIATIONS

A, Peak late atrial filling velocity; Cl, Cardiac index; CO, Cardiac output; DT-E, Deceleration time of E velocity; E, Peak early filling velocity; EF, Left ventricular ejection fraction; GPBB, Glycogenphosphorylase BB isoenzyme; IVC, Inferior vena cava diameter; IVRT, Isovolumic relaxation time; LA, Left atrium diameter; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left ventricular end-systolic diameter; PCWP, Pulmonary capillary wedge pressure; PVR, Pulmonary vascular resistance; RV, Right ventricle diameter; SVR, Systemic vascular resistance; TIPS, transjugular intrahepatic portosystemic shunt.

ACKNOWLEDGEMENT

The study was supported by MH CZ - DRO (UHKK, 00179906) and the programme PRVOUK P37/3.

Author contributions: MV, IK: biochemical analysis; RP: cardiology, project leader; VS, TF, PH: statistical analysis; BD: manuscript revision, editing and translation.

Conflict of interest statement: The authors declare that there are no conflicts of interest regarding the publication of this article.

REFERENCES

